Highly purified fucosylated chondroitin sulfate oligomers with selective intrinsic factor Xase complex inhibition

Carbohydr Polym. 2019 Oct 15:222:115025. doi: 10.1016/j.carbpol.2019.115025. Epub 2019 Jun 27.

Abstract

Fucosylated chondroitin sulfate (FCS) oligosaccharides of specific molecular weight have shown potent anticoagulant activities with selectivity towards intrinsic factor Xase complex. However, the preparation of FCS oligosaccharides by traditional methods requires multiple purification steps consuming large amounts of time and significant resources. The current study focuses on developing a method for the rapid preparation of FCS oligomers from sea cucumber Pearsonothuria graeffei having 6-18 saccharide residues. The key steps controlling molecular weight (Mw) and purity of these FCS oligomers were evaluated. Structural analysis showed the resulting FCS oligomers were primarily l-Fuc3,4diS-α1,3-d-GlcA-β1,3-(d-GalNAc4,6diS-β1,4-[l-Fuc3,4diS-α1,3-]d-GlcA-β1,3-)nd-anTal-ol4,6diS (n = 1˜5) accompanied by partial de-fucosylation and/or de-sulfation. In vitro and in vivo experiments demonstrate that these FCS oligomers selectively inhibit intrinsic factor Xase complex and exhibit remarkable antithrombotic activity without hemorrhagic and hypotension side effects. This method is suitable for large-scale preparation of FCS oligosaccharides as clinical anticoagulants.

Keywords: Anticoagulant and antithrombotic activities; Fucosylated chondroitin sulfate oligomers; Intrinsic factor Xase complex; Partial N-deacetylation–deaminative cleavage; Ultrafiltration separation.

MeSH terms

  • Animals
  • Anticoagulants / chemistry
  • Anticoagulants / pharmacology
  • Anticoagulants / therapeutic use*
  • Carbohydrate Sequence
  • Chondroitin Sulfates / chemistry
  • Chondroitin Sulfates / pharmacology
  • Chondroitin Sulfates / therapeutic use*
  • Cysteine Endopeptidases
  • Factor IXa / antagonists & inhibitors*
  • Factor VIIIa / antagonists & inhibitors*
  • Fibrinolytic Agents / chemistry
  • Fibrinolytic Agents / pharmacology
  • Fibrinolytic Agents / therapeutic use*
  • Male
  • Mice
  • Neoplasm Proteins / antagonists & inhibitors*
  • Rabbits
  • Rats, Sprague-Dawley
  • Sea Cucumbers / chemistry
  • Venous Thrombosis / drug therapy

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Neoplasm Proteins
  • fucosylated chondroitin sulfate
  • Factor VIIIa
  • Chondroitin Sulfates
  • Factor IXa
  • Cysteine Endopeptidases
  • cancer procoagulant